Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses Article Swipe
Monica Peravali
,
Cristiane Gomes-Lima
,
Eshetu Tefera
,
Mairead Baker
,
Mamta Sherchan
,
Saira Farid
,
Kenneth D. Burman
,
Florina Constantinescu
,
Irina Veytsman
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.5306/wjco.v12.i2.103
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.5306/wjco.v12.i2.103
BACKGROUND: Immune checkpoint inhibitors (ICPi) cause various immune-related adverse events (irAE) with thyroid dysfunction as a commonly reported abnormality. There is increasing evidence showing positive association with development of irAE and survival. However, prior trials with ICPi had underrepresentation of minorities with < 5% African Americans. AIM: To evaluate the association between development of irAE and survival outcomes among a racially diverse patient population. METHODS: Data on patients with stage IV solid malignancies treated with programmed cell death-protein 1/programmed death ligand 1 blockers between January 2013 and December 2018 across MedStar Georgetown Cancer Institute facilities were retrospectively reviewed. Patients treated with cytotoxic T-lymphocyte-associated protein 4 inhibitors were excluded. Progression free survival (PFS) and overall survival (OS) were primary endpoints and were calculated using Kaplan-Meier methods and Wilcoxon rank sum test for comparison. RESULTS: Out of 293 patients who met eligibility criteria, 91 pts (31%) had any grade irAE; most common AE were endocrine (40.7%) specifically TSH elevation, dermatological (23.1%) and rheumatologic (18.7%). Proportion of irAE was significantly higher in Caucasians vs African Americans (60.4% vs 30.8%), in patients with low programmed death ligand 1, lower LDH, older age, and those who had more treatment cycles with ICPi. Rate of progression was lower in patients with irAE (30.8% vs 46.0%, P = 0.0140). Median PFS (5.8 vs 3.0 mo, P = 0.0204) and OS (17.1 vs 7.2 mo, P < 0.0001) were higher with irAE. Statistically significant difference in OS (17.1 vs 8.6 mo, P = 0.0002) but not in PFS (5.8 vs 3.3 mo, P = 0.0545) was noted with endocrine irAE. No differences in survival were observed among other commonly reported irAE. Differences in survival among subgroups of patients with irAE are described. CONCLUSION: Development of irAE positively correlated with improved PFS and OS as reported in previous studies. To our knowledge, this is the first study observing differences in OS favoring endocrine AE and Caucasian race. These factors may be potential surrogate markers of prognosis pending replication of these results in large-scale studies.
Related Topics
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.5306/wjco.v12.i2.103
- OA Status
- diamond
- Cited By
- 24
- References
- 19
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3131585552
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3131585552Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.5306/wjco.v12.i2.103Digital Object Identifier
- Title
-
Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responsesWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-02-22Full publication date if available
- Authors
-
Monica Peravali, Cristiane Gomes-Lima, Eshetu Tefera, Mairead Baker, Mamta Sherchan, Saira Farid, Kenneth D. Burman, Florina Constantinescu, Irina VeytsmanList of authors in order
- Landing page
-
https://doi.org/10.5306/wjco.v12.i2.103Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.5306/wjco.v12.i2.103Direct OA link when available
- Concepts
-
Medicine, Immune system, Adverse effect, Immunology, Oncology, Internal medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
24Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 6, 2024: 6, 2023: 4, 2022: 5, 2021: 3Per-year citation counts (last 5 years)
- References (count)
-
19Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3131585552 |
|---|---|
| doi | https://doi.org/10.5306/wjco.v12.i2.103 |
| ids.doi | https://doi.org/10.5306/wjco.v12.i2.103 |
| ids.mag | 3131585552 |
| ids.openalex | https://openalex.org/W3131585552 |
| fwci | 1.88696688 |
| type | article |
| title | Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses |
| biblio.issue | 2 |
| biblio.volume | 12 |
| biblio.last_page | 114 |
| biblio.first_page | 103 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T11491 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9901000261306763 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | CAR-T cell therapy research |
| topics[2].id | https://openalex.org/T11067 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9882000088691711 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Colorectal Cancer Treatments and Studies |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8690933585166931 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C8891405 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7327814102172852 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[1].display_name | Immune system |
| concepts[2].id | https://openalex.org/C197934379 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6769782900810242 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[2].display_name | Adverse effect |
| concepts[3].id | https://openalex.org/C203014093 |
| concepts[3].level | 1 |
| concepts[3].score | 0.4541177749633789 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[3].display_name | Immunology |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.3531652092933655 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.30677157640457153 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8690933585166931 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/immune-system |
| keywords[1].score | 0.7327814102172852 |
| keywords[1].display_name | Immune system |
| keywords[2].id | https://openalex.org/keywords/adverse-effect |
| keywords[2].score | 0.6769782900810242 |
| keywords[2].display_name | Adverse effect |
| keywords[3].id | https://openalex.org/keywords/immunology |
| keywords[3].score | 0.4541177749633789 |
| keywords[3].display_name | Immunology |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.3531652092933655 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.30677157640457153 |
| keywords[5].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.5306/wjco.v12.i2.103 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2765028222 |
| locations[0].source.issn | 2218-4333 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2218-4333 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | World Journal of Clinical Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310315735 |
| locations[0].source.host_organization_name | Baishideng Publishing Group |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315735 |
| locations[0].source.host_organization_lineage_names | Baishideng Publishing Group |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | World Journal of Clinical Oncology |
| locations[0].landing_page_url | https://doi.org/10.5306/wjco.v12.i2.103 |
| locations[1].id | pmh:oai:pubmedcentral.nih.gov:7918525 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S2764455111 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed Central |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | acceptedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | False |
| locations[1].raw_source_name | World J Clin Oncol |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7918525 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5061749635 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-6511-2826 |
| authorships[0].author.display_name | Monica Peravali |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1285739803 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Hematology/Oncology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[0].institutions[0].id | https://openalex.org/I1285739803 |
| authorships[0].institutions[0].ror | https://ror.org/05ry42w04 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I1285739803, https://openalex.org/I86755215 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | MedStar Washington Hospital Center |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Monica Peravali |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Hematology/Oncology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[1].author.id | https://openalex.org/A5060762849 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-7684-8268 |
| authorships[1].author.display_name | Cristiane Gomes-Lima |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1285739803 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[1].institutions[0].id | https://openalex.org/I1285739803 |
| authorships[1].institutions[0].ror | https://ror.org/05ry42w04 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1285739803, https://openalex.org/I86755215 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | MedStar Washington Hospital Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Cristiane Gomes-Lima |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[2].author.id | https://openalex.org/A5068919849 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-5041-8438 |
| authorships[2].author.display_name | Eshetu Tefera |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I86755215 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Biostatistics and Bioinformatics, MedStar Health Research Institute, Washington, DC 20010, United States. |
| authorships[2].institutions[0].id | https://openalex.org/I86755215 |
| authorships[2].institutions[0].ror | https://ror.org/05atemp08 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I86755215 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | MedStar Health |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Eshetu Tefera |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Biostatistics and Bioinformatics, MedStar Health Research Institute, Washington, DC 20010, United States. |
| authorships[3].author.id | https://openalex.org/A5111188041 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Mairead Baker |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1285739803 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[3].institutions[0].id | https://openalex.org/I1285739803 |
| authorships[3].institutions[0].ror | https://ror.org/05ry42w04 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I1285739803, https://openalex.org/I86755215 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | MedStar Washington Hospital Center |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mairead Baker |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[4].author.id | https://openalex.org/A5055417880 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Mamta Sherchan |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1285739803 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Rheumatology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[4].institutions[0].id | https://openalex.org/I1285739803 |
| authorships[4].institutions[0].ror | https://ror.org/05ry42w04 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I1285739803, https://openalex.org/I86755215 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | MedStar Washington Hospital Center |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Mamta Sherchan |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Rheumatology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[5].author.id | https://openalex.org/A5003952817 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Saira Farid |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I1285739803 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[5].institutions[0].id | https://openalex.org/I1285739803 |
| authorships[5].institutions[0].ror | https://ror.org/05ry42w04 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I1285739803, https://openalex.org/I86755215 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | MedStar Washington Hospital Center |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Saira Farid |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[6].author.id | https://openalex.org/A5013056369 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-8597-7213 |
| authorships[6].author.display_name | Kenneth D. Burman |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I1285739803 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[6].institutions[0].id | https://openalex.org/I1285739803 |
| authorships[6].institutions[0].ror | https://ror.org/05ry42w04 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I1285739803, https://openalex.org/I86755215 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | MedStar Washington Hospital Center |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Kenneth Burman |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[7].author.id | https://openalex.org/A5005324738 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-3978-6226 |
| authorships[7].author.display_name | Florina Constantinescu |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I1285739803 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Rheumatology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[7].institutions[0].id | https://openalex.org/I1285739803 |
| authorships[7].institutions[0].ror | https://ror.org/05ry42w04 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I1285739803, https://openalex.org/I86755215 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | MedStar Washington Hospital Center |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Florina Constantinescu |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Rheumatology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[8].author.id | https://openalex.org/A5068549294 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Irina Veytsman |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I1285739803 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Hematology/Oncology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| authorships[8].institutions[0].id | https://openalex.org/I1285739803 |
| authorships[8].institutions[0].ror | https://ror.org/05ry42w04 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I1285739803, https://openalex.org/I86755215 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | MedStar Washington Hospital Center |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Irina Veytsman |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Hematology/Oncology, MedStar Washington Hospital Center, Washington, DC 20010, United States. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.5306/wjco.v12.i2.103 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2021-03-01T00:00:00 |
| display_name | Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W1966504330, https://openalex.org/W1979139803, https://openalex.org/W2037631372, https://openalex.org/W2073527559, https://openalex.org/W2030889776, https://openalex.org/W2159000141, https://openalex.org/W2070567609, https://openalex.org/W1974041167, https://openalex.org/W2391409986, https://openalex.org/W1966775726 |
| cited_by_count | 24 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 6 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 6 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 4 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 5 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 3 |
| locations_count | 2 |
| best_oa_location.id | doi:10.5306/wjco.v12.i2.103 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2765028222 |
| best_oa_location.source.issn | 2218-4333 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2218-4333 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | World Journal of Clinical Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310315735 |
| best_oa_location.source.host_organization_name | Baishideng Publishing Group |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315735 |
| best_oa_location.source.host_organization_lineage_names | Baishideng Publishing Group |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | World Journal of Clinical Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.5306/wjco.v12.i2.103 |
| primary_location.id | doi:10.5306/wjco.v12.i2.103 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2765028222 |
| primary_location.source.issn | 2218-4333 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2218-4333 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | World Journal of Clinical Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310315735 |
| primary_location.source.host_organization_name | Baishideng Publishing Group |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315735 |
| primary_location.source.host_organization_lineage_names | Baishideng Publishing Group |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | World Journal of Clinical Oncology |
| primary_location.landing_page_url | https://doi.org/10.5306/wjco.v12.i2.103 |
| publication_date | 2021-02-22 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W2783137027, https://openalex.org/W2903686952, https://openalex.org/W2594042408, https://openalex.org/W2760410509, https://openalex.org/W2979886379, https://openalex.org/W3008440946, https://openalex.org/W2915955284, https://openalex.org/W2179179825, https://openalex.org/W2751281338, https://openalex.org/W2561156916, https://openalex.org/W2132916434, https://openalex.org/W3036354112, https://openalex.org/W2891948100, https://openalex.org/W2946614049, https://openalex.org/W2988124258, https://openalex.org/W2896274372, https://openalex.org/W2293531514, https://openalex.org/W2947042456, https://openalex.org/W2761265752 |
| referenced_works_count | 19 |
| abstract_inverted_index.1 | 81 |
| abstract_inverted_index.4 | 104 |
| abstract_inverted_index.< | 42, 228 |
| abstract_inverted_index.= | 210, 219, 244, 255 |
| abstract_inverted_index.P | 209, 218, 227, 243, 254 |
| abstract_inverted_index.a | 15, 59 |
| abstract_inverted_index.1, | 183 |
| abstract_inverted_index.5% | 43 |
| abstract_inverted_index.91 | 141 |
| abstract_inverted_index.AE | 150, 314 |
| abstract_inverted_index.IV | 70 |
| abstract_inverted_index.No | 262 |
| abstract_inverted_index.OS | 222, 238, 294, 311 |
| abstract_inverted_index.To | 47, 300 |
| abstract_inverted_index.as | 14, 295 |
| abstract_inverted_index.be | 321 |
| abstract_inverted_index.in | 168, 176, 202, 237, 248, 264, 274, 297, 310, 332 |
| abstract_inverted_index.is | 20, 304 |
| abstract_inverted_index.of | 28, 39, 53, 134, 163, 198, 278, 286, 325, 329 |
| abstract_inverted_index.on | 66 |
| abstract_inverted_index.vs | 170, 174, 207, 215, 224, 240, 251 |
| abstract_inverted_index.293 | 135 |
| abstract_inverted_index.3.0 | 216 |
| abstract_inverted_index.3.3 | 252 |
| abstract_inverted_index.7.2 | 225 |
| abstract_inverted_index.8.6 | 241 |
| abstract_inverted_index.Out | 133 |
| abstract_inverted_index.PFS | 213, 249, 292 |
| abstract_inverted_index.TSH | 155 |
| abstract_inverted_index.and | 30, 55, 86, 112, 119, 125, 159, 188, 221, 293, 315 |
| abstract_inverted_index.any | 145 |
| abstract_inverted_index.are | 282 |
| abstract_inverted_index.but | 246 |
| abstract_inverted_index.for | 130 |
| abstract_inverted_index.had | 37, 144, 191 |
| abstract_inverted_index.low | 179 |
| abstract_inverted_index.may | 320 |
| abstract_inverted_index.met | 138 |
| abstract_inverted_index.mo, | 217, 226, 242, 253 |
| abstract_inverted_index.not | 247 |
| abstract_inverted_index.our | 301 |
| abstract_inverted_index.pts | 142 |
| abstract_inverted_index.sum | 128 |
| abstract_inverted_index.the | 49, 305 |
| abstract_inverted_index.was | 165, 200, 257 |
| abstract_inverted_index.who | 137, 190 |
| abstract_inverted_index.(5.8 | 214, 250 |
| abstract_inverted_index.(OS) | 115 |
| abstract_inverted_index.2013 | 85 |
| abstract_inverted_index.2018 | 88 |
| abstract_inverted_index.AIM: | 46 |
| abstract_inverted_index.Data | 65 |
| abstract_inverted_index.ICPi | 36 |
| abstract_inverted_index.LDH, | 185 |
| abstract_inverted_index.Rate | 197 |
| abstract_inverted_index.age, | 187 |
| abstract_inverted_index.cell | 76 |
| abstract_inverted_index.free | 109 |
| abstract_inverted_index.irAE | 29, 54, 164, 205, 281, 287 |
| abstract_inverted_index.more | 192 |
| abstract_inverted_index.most | 148 |
| abstract_inverted_index.rank | 127 |
| abstract_inverted_index.test | 129 |
| abstract_inverted_index.this | 303 |
| abstract_inverted_index.were | 95, 106, 116, 120, 151, 230, 266 |
| abstract_inverted_index.with | 11, 26, 35, 41, 68, 74, 100, 178, 195, 204, 232, 259, 280, 290 |
| abstract_inverted_index.(17.1 | 223, 239 |
| abstract_inverted_index.(31%) | 143 |
| abstract_inverted_index.(PFS) | 111 |
| abstract_inverted_index.ICPi. | 196 |
| abstract_inverted_index.There | 19 |
| abstract_inverted_index.These | 318 |
| abstract_inverted_index.among | 58, 268, 276 |
| abstract_inverted_index.cause | 5 |
| abstract_inverted_index.death | 79, 181 |
| abstract_inverted_index.first | 306 |
| abstract_inverted_index.grade | 146 |
| abstract_inverted_index.irAE. | 233, 261, 272 |
| abstract_inverted_index.irAE; | 147 |
| abstract_inverted_index.lower | 184, 201 |
| abstract_inverted_index.noted | 258 |
| abstract_inverted_index.older | 186 |
| abstract_inverted_index.other | 269 |
| abstract_inverted_index.prior | 33 |
| abstract_inverted_index.race. | 317 |
| abstract_inverted_index.solid | 71 |
| abstract_inverted_index.stage | 69 |
| abstract_inverted_index.study | 307 |
| abstract_inverted_index.these | 330 |
| abstract_inverted_index.those | 189 |
| abstract_inverted_index.using | 122 |
| abstract_inverted_index.(30.8% | 206 |
| abstract_inverted_index.(60.4% | 173 |
| abstract_inverted_index.(ICPi) | 4 |
| abstract_inverted_index.(irAE) | 10 |
| abstract_inverted_index.46.0%, | 208 |
| abstract_inverted_index.Cancer | 92 |
| abstract_inverted_index.Immune | 1 |
| abstract_inverted_index.Median | 212 |
| abstract_inverted_index.across | 89 |
| abstract_inverted_index.common | 149 |
| abstract_inverted_index.cycles | 194 |
| abstract_inverted_index.events | 9 |
| abstract_inverted_index.higher | 167, 231 |
| abstract_inverted_index.ligand | 80, 182 |
| abstract_inverted_index.trials | 34 |
| abstract_inverted_index.(23.1%) | 158 |
| abstract_inverted_index.(40.7%) | 153 |
| abstract_inverted_index.0.0001) | 229 |
| abstract_inverted_index.0.0002) | 245 |
| abstract_inverted_index.0.0204) | 220 |
| abstract_inverted_index.0.0545) | 256 |
| abstract_inverted_index.30.8%), | 175 |
| abstract_inverted_index.African | 44, 171 |
| abstract_inverted_index.January | 84 |
| abstract_inverted_index.MedStar | 90 |
| abstract_inverted_index.adverse | 8 |
| abstract_inverted_index.between | 51, 83 |
| abstract_inverted_index.diverse | 61 |
| abstract_inverted_index.factors | 319 |
| abstract_inverted_index.markers | 324 |
| abstract_inverted_index.methods | 124 |
| abstract_inverted_index.overall | 113 |
| abstract_inverted_index.patient | 62 |
| abstract_inverted_index.pending | 327 |
| abstract_inverted_index.primary | 117 |
| abstract_inverted_index.protein | 103 |
| abstract_inverted_index.results | 331 |
| abstract_inverted_index.showing | 23 |
| abstract_inverted_index.thyroid | 12 |
| abstract_inverted_index.treated | 73, 99 |
| abstract_inverted_index.various | 6 |
| abstract_inverted_index.(18.7%). | 161 |
| abstract_inverted_index.0.0140). | 211 |
| abstract_inverted_index.December | 87 |
| abstract_inverted_index.However, | 32 |
| abstract_inverted_index.METHODS: | 64 |
| abstract_inverted_index.Patients | 98 |
| abstract_inverted_index.RESULTS: | 132 |
| abstract_inverted_index.Wilcoxon | 126 |
| abstract_inverted_index.blockers | 82 |
| abstract_inverted_index.commonly | 16, 270 |
| abstract_inverted_index.evaluate | 48 |
| abstract_inverted_index.evidence | 22 |
| abstract_inverted_index.favoring | 312 |
| abstract_inverted_index.improved | 291 |
| abstract_inverted_index.observed | 267 |
| abstract_inverted_index.outcomes | 57 |
| abstract_inverted_index.patients | 67, 136, 177, 203, 279 |
| abstract_inverted_index.positive | 24 |
| abstract_inverted_index.previous | 298 |
| abstract_inverted_index.racially | 60 |
| abstract_inverted_index.reported | 17, 271, 296 |
| abstract_inverted_index.studies. | 299, 334 |
| abstract_inverted_index.survival | 56, 110, 114, 265, 275 |
| abstract_inverted_index.Americans | 172 |
| abstract_inverted_index.Caucasian | 316 |
| abstract_inverted_index.Institute | 93 |
| abstract_inverted_index.criteria, | 140 |
| abstract_inverted_index.cytotoxic | 101 |
| abstract_inverted_index.endocrine | 152, 260, 313 |
| abstract_inverted_index.endpoints | 118 |
| abstract_inverted_index.excluded. | 107 |
| abstract_inverted_index.observing | 308 |
| abstract_inverted_index.potential | 322 |
| abstract_inverted_index.prognosis | 326 |
| abstract_inverted_index.reviewed. | 97 |
| abstract_inverted_index.subgroups | 277 |
| abstract_inverted_index.surrogate | 323 |
| abstract_inverted_index.survival. | 31 |
| abstract_inverted_index.treatment | 193 |
| abstract_inverted_index.Americans. | 45 |
| abstract_inverted_index.Caucasians | 169 |
| abstract_inverted_index.Georgetown | 91 |
| abstract_inverted_index.Proportion | 162 |
| abstract_inverted_index.calculated | 121 |
| abstract_inverted_index.checkpoint | 2 |
| abstract_inverted_index.correlated | 289 |
| abstract_inverted_index.described. | 283 |
| abstract_inverted_index.difference | 236 |
| abstract_inverted_index.elevation, | 156 |
| abstract_inverted_index.facilities | 94 |
| abstract_inverted_index.increasing | 21 |
| abstract_inverted_index.inhibitors | 3, 105 |
| abstract_inverted_index.knowledge, | 302 |
| abstract_inverted_index.minorities | 40 |
| abstract_inverted_index.positively | 288 |
| abstract_inverted_index.programmed | 75, 180 |
| abstract_inverted_index.BACKGROUND: | 0 |
| abstract_inverted_index.CONCLUSION: | 284 |
| abstract_inverted_index.Development | 285 |
| abstract_inverted_index.Differences | 273 |
| abstract_inverted_index.Progression | 108 |
| abstract_inverted_index.association | 25, 50 |
| abstract_inverted_index.comparison. | 131 |
| abstract_inverted_index.development | 27, 52 |
| abstract_inverted_index.differences | 263, 309 |
| abstract_inverted_index.dysfunction | 13 |
| abstract_inverted_index.eligibility | 139 |
| abstract_inverted_index.large-scale | 333 |
| abstract_inverted_index.population. | 63 |
| abstract_inverted_index.progression | 199 |
| abstract_inverted_index.replication | 328 |
| abstract_inverted_index.significant | 235 |
| abstract_inverted_index.1/programmed | 78 |
| abstract_inverted_index.Kaplan-Meier | 123 |
| abstract_inverted_index.abnormality. | 18 |
| abstract_inverted_index.malignancies | 72 |
| abstract_inverted_index.specifically | 154 |
| abstract_inverted_index.Statistically | 234 |
| abstract_inverted_index.death-protein | 77 |
| abstract_inverted_index.rheumatologic | 160 |
| abstract_inverted_index.significantly | 166 |
| abstract_inverted_index.dermatological | 157 |
| abstract_inverted_index.immune-related | 7 |
| abstract_inverted_index.retrospectively | 96 |
| abstract_inverted_index.underrepresentation | 38 |
| abstract_inverted_index.T-lymphocyte-associated | 102 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 95 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.46000000834465027 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.86790434 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |